Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios A Dimopoulos

Showing results (491-500 of 740) with videos related to

Pageof 74
Sort By:
Hemasphere|March 4, 2024
Single-cell analysis of MYD88<sup>L265P</sup> and MYD88<sup>WT</sup> Waldenström macroglobulinemia patientsTina Bagratuni, Foteini Aktypi, Ourania Theologi, et al.
Haematologica|August 22, 2015
Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapyEfstathios Kastritis, Marie-Christine Kyrtsonis, Pierre Morel, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 15, 2024
Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in GreeceEfstathios Kastritis, Ioannis Ntanasis-Stathopoulos, Foteini Theodorakakou, et al.
International Journal of Cancer|April 13, 2011
Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agentsEvangelos Terpos, Konstantinos Anargyrou, Eirini Katodritou, et al.
Blood Cancer Journal|February 27, 2023
Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathyMaria Moscvin, Christine Ivy Liacos, Tianzeng Chen, et al.
Journal of Bone Oncology|November 11, 2025
Bone disease burden does not impact overall survival in newly diagnosed patients with multiple myeloma - a single center, retrospective imaging analysis on 119 patientsEvangelos Terpos, Vassilis Koutoulidis, Ioannis Ntanasis-Stathopoulos, et al.
British Journal of Haematology|February 16, 2017
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite studyHang Quach, Liam Fernyhough, Ross Henderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2022
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 TrialMeletios A Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, et al.
Blood Advances|January 4, 2018
Cardiac and renal complications of carfilzomib in patients with multiple myelomaMeletios A Dimopoulos, Maria Roussou, Maria Gavriatopoulou, et al.
Hemasphere|August 5, 2022
Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA TherapyIoannis Ntanasis-Stathopoulos, Vangelis Karalis, Maria Gavriatopoulou, et al.
Pageof 74

Showing results (491-500 of 740) with videos related to

Sort By:
Pageof 74
Hemasphere|March 4, 2024
Single-cell analysis of MYD88<sup>L265P</sup> and MYD88<sup>WT</sup> Waldenström macroglobulinemia patientsTina Bagratuni, Foteini Aktypi, Ourania Theologi, et al.
Haematologica|August 22, 2015
Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapyEfstathios Kastritis, Marie-Christine Kyrtsonis, Pierre Morel, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 15, 2024
Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in GreeceEfstathios Kastritis, Ioannis Ntanasis-Stathopoulos, Foteini Theodorakakou, et al.
International Journal of Cancer|April 13, 2011
Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agentsEvangelos Terpos, Konstantinos Anargyrou, Eirini Katodritou, et al.
Blood Cancer Journal|February 27, 2023
Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathyMaria Moscvin, Christine Ivy Liacos, Tianzeng Chen, et al.
Journal of Bone Oncology|November 11, 2025
Bone disease burden does not impact overall survival in newly diagnosed patients with multiple myeloma - a single center, retrospective imaging analysis on 119 patientsEvangelos Terpos, Vassilis Koutoulidis, Ioannis Ntanasis-Stathopoulos, et al.
British Journal of Haematology|February 16, 2017
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite studyHang Quach, Liam Fernyhough, Ross Henderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2022
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 TrialMeletios A Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, et al.
Blood Advances|January 4, 2018
Cardiac and renal complications of carfilzomib in patients with multiple myelomaMeletios A Dimopoulos, Maria Roussou, Maria Gavriatopoulou, et al.
Hemasphere|August 5, 2022
Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA TherapyIoannis Ntanasis-Stathopoulos, Vangelis Karalis, Maria Gavriatopoulou, et al.
Pageof 74